Unlock instant, AI-driven research and patent intelligence for your innovation.

Combination therapy using anti - CD20 antibody and human IL-15

A CD20 and antibody technology, applied in the direction of antibody medical components, anti-animal/human immunoglobulin, antibodies, etc., can solve the problems of pleiotropic separation and complex characterization, low plasma concentration, etc.

Inactive Publication Date: 2014-11-05
ROCHE GLYCART AG
View PDF35 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0019] Short half-lives, low plasma concentrations, pleiotropy, and redundancy complicate isolation and characterization of cytokines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy using anti - CD20 antibody and human IL-15
  • Combination therapy using anti - CD20 antibody and human IL-15
  • Combination therapy using anti - CD20 antibody and human IL-15

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0034] The present invention includes afucosylated IgG1 or IgG3 isotype antibodies (preferably IgG1 isotype) for the manufacture of a medicament for the treatment of cancer in combination with the cytokine human IL-15, wherein said cancer expresses said tumor antigen.

[0035] In one embodiment, the amount of fucose is 20% to 60% of the total amount of oligosaccharides (sugars) at Asn297.

[0036] The term "antibody" encompasses various forms of antibodies including, but not limited to, whole antibodies, human antibodies, humanized antibodies, and genetically engineered antibodies, such as monoclonal, chimeric, or recombinant antibodies, and fragments of such antibodies, provided that they are defined in accordance with The characteristic properties of the invention are preserved. As used herein, the term "monoclonal antibody" or "monoclonal antibody composition" refers to a preparation of antibody molecules composed of a single amino acid. Thus, the term "human monoclonal a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody specifically binding to a tumor-antigen with human IL-15 for the treatment of cancer.

Description

field of invention [0001] The present invention is directed to the combination therapy of patients with cancer, especially with hematologic malignancies, such as leukemias such as chronic lymphocytic leukemia (CLL), using an anti-CD20 antibody and the cytokine human IL-15. Background of the invention [0002] Afucosylated Antibodies [0003] The cell-mediated effector functions of monoclonal antibodies can be enhanced by engineering their oligosaccharide components, as documented in , P. et al., Nature Biotechnol. 17(1999) 176-180 and US6,602,684. IgG1 type antibodies (ie, the antibodies most commonly used in cancer immunotherapy) are glycoproteins with a conserved N-linked glycosylation site at Asn297 in each CH2 domain. Two complex biantennary oligosaccharides attached to Asn297 are buried between each CH2 domain, forming extensive contacts with the polypeptide backbone, and their presence is essential for antibody-mediated effector functions such as antibody-dependent ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K38/20A61P35/02C07K16/28
CPCC07K2317/24C07K2317/732C07K2317/54A61K45/06C07K16/2887A61K38/2086C07K2317/41A61K39/39558A61K38/2033A61P35/00A61P35/02A61P43/00A61K2300/00A61N5/10A61N2005/1098
Inventor C.克雷恩E.拉普里沃特A.奎雷特-玛丽
Owner ROCHE GLYCART AG